菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics and Sino Biopharm Sign Discovery Service Agreement for First-in-Class Biologics
Dec. 30, 2024
WuXi Biologics and Sino Biopharm Sign Discovery Service Agreement for First-in-Class Biologics
  • Sino Biopharm will have the exclusive rights to the monoclonal antibody (mAb) against undisclosed target, derived from WuXi Biologics’ integrated discovery technology platforms
  • WuXi Biologics introduces new tailored service-based mode in integrated discovery services to enable client’s global strategies
     
SHANGHAI Dec. 30, 2024 – WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a service agreement with Sino Biopharm, a leading innovative R&D-driven pharmaceutical group in China, to discover a first-in-class mAb against an undisclosed target.
    
Under the terms of the agreement, WuXi Biologics will provide integrated discovery services, including antibody generation, lead identification and optimization, and developability assessment by leveraging its discovery technology platforms such as single B cell technology platform, which will enable Sino Biopharm to elect to an optimal preclinical mAb candidate with a designated target. Sino Biopharm will have the exclusive rights of the mAb generated from this collaboration and assume full responsibility for the Investigational New Drug (IND) applications, clinical trials and commercialization. WuXi Biologics will receive payments based on the progress of project development and commercialization. 
    
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We’re delighted to provide our proven integrated discovery platforms for Sino Biopharm to discover a first-in-class mAb. This agreement further reinforces the value of R (research) in our unique CRDMO model and highlights WuXi Bio’s role as the partner of choice in discovery services, including Chinese pharmaceutical companies in building innovative pipelines. It also strengthens the robust partnership between WuXi Biologics and Sino Biopharm. We look forward to offering global open-access technology platforms with unsurpassed speed and efficiency to support Sino Biopharm to transform their innovative ideas into new treatments for patients worldwide.”
   
Mr. Tse, Eric S Y, CEO of Sino Biopharm, commented, “This cooperation marks a significant step in our company’s internationalization strategy. We are extremely delighted to have reached a service agreement with WuXi Biologics, leveraging its comprehensive and streamlined suite of solutions for biologic discovery. We believe that by combining WuXi Biologics’ profound know-how in antibody discovery and engineering together with Sino Biopharm’s expertise in biology and strong capabilities in drug research and development, we can continuously accelerate the development of differentiated innovative treatments, thus better benefiting patients worldwide.”
      
About WuXi Biologics
    
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
     
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO projects and non-COVID dormant CMO project).
     
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
     
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
    
About Sino Biopharm
    
Sino Biopharm is a leading innovation and R&D-driven pharmaceutical company in China, with its business covering the entire industrial chain of pharmaceutical R&D platforms, intelligent manufacturing, and a strong sales system. The product portfolio encompasses a variety of biopharmaceuticals and small molecule drugs, holding a dominant position in four major therapeutic areas of oncology, hepatology, respiratory and surgery/analgesia.
    
The company was listed on the Hong Kong Stock Exchange in 2000 with the stock code 01177.HK. The subsidiaries locate in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao, and other cities, with multiple pharmaceutical production bases. Since its establishment, the company has consistently achieved remarkable achievements and steady development. The core enterprises, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., have been both ranked among the top 100 Chinese pharmaceutical industrial enterprises for many years.
    
For more information, please visit: https://www.sinobiopharm.com/.
    
WuXi Biologics Contacts
  
Business
 
Media